Belgian data of ODYSSEY APPRISE: stringent LDL‐c targets are in reach when using all available tools

Abstract

Background As lipid targets became more stringent in the latest ESC/EAS guidelines, many patients on statin monotherapy are left above their risk‐based target, increasing the need for lipid‐lowering therapies. The results of the ODYSSEY APPRISE study were recently published by Gaudet et al In this trial, alirocumab (a PCSK9 inhibitor) was investigated in high cardiovascular risk patients in a real‐life setting. Objective We aim at analysing the characteristics, safety and efficacy of alirocumab in the Belgian population of the ODYSSEY APPRISE trial and, based on literature research, we aim to evaluate the importance and the need for the add‐on, non‐statin lipid‐lowering therapy in clinical practice. Methods and Results ODYSSEY APPRISE is a multicentric, prospective, single‐arm, Phase 3b open‐label trial. A total of 68 Belgian patients were enrolled, 63 patients had heterozygous familial hypercholesterolaemia (HeFH). Baseline mean LDL‐c was 188.7 mg/dL (SD ± 51.8). At week 12, 65 patients had an evaluable efficacy end point with a mean LDL‐c reduction of 59.9% from baseline. The overall incidence of treatment‐emergent adverse events (TEAEs) was 75.0%. The most frequent TEAE was back pain (10.3%), nasopharyngitis (10.3%) and injection site erythema (8.8%). Based on the literature, a majority of patients do not reach their risk‐based lipid target despite statin therapy alone. Conclusion In a real‐life setting, alirocumab is both well‐tolerated, safe and very effective in reducing LDL‐c in this Belgian cohort. In clinical practice, more patients should be initiated on the add‐on, non‐statin lipid‐lowering therapy in order to reach their risk‐based lipid target.